Rapport Therapeutics (RAPP) Other Non-Current Liabilities (2023 - 2024)
Rapport Therapeutics' (RAPP) quarterly Other Non-Current Liabilities came in at $9.4 million in Q4 2024, up 124.57% year-on-year from $4.2 million in Q1 2024, and up 124.57% on a QoQ basis from $4.2 million in Q4 2023.
Rapport Therapeutics (RAPP) Other Non-Current Liabilities (2023 - 2024) Analysis & Trends
Rapport Therapeutics (RAPP) has 2 years of Other Non-Current Liabilities data on file, last reported at $9.4 million in Q4 2024.
- On a quarterly basis, Other Non-Current Liabilities rose 124.57% year-over-year to $9.4 million in Q4 2024; TTM through Dec 2024 was $9.4 million, a 124.57% increase from a year earlier, with the FY2024 full-year figure at $9.4 million, up 124.57% from the prior year.
- Other Non-Current Liabilities for Q4 2024 stood at $9.4 million, up from $4.2 million in the prior quarter.
- Over the last five years, Other Non-Current Liabilities for RAPP reached as high as $9.4 million in Q4 2024 and fell as low as $4.2 million in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | Rapport Therapeutics | 1.94 Bn | 1.94 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 9.43 Mn |
| Dec 31, 2023 | 4.20 Mn |